SEEING TRIPLE
agency: Harrison and Star
brand: Avastin
client: Roche (Global) and Genentech (US)
photo from left: Craig Foster, partner, Inside Productions • Chris Watson, SVP, creative director • Alaina Mendoza, VP, group account supervisor • Michael Norkin, VP, associate creative director
The biggest hurdle facing any professional marketing team is making dry scientific facts and figures really pop. The team at Harrison and Star took that challenge literally—and in the process, combined cutting-edge graphics and stellar filmmaking to create 3-D animation of Avastin's mechanism of action.
Genentech was pleased, as was the industry—the Avastin DVD garnered high accolades from a variety of sources, including the Rx Club Awards. It also made a splash on the convention hall floor. (We've seen it—have you?)
"We know from experience that it's been very successful at conventions," says Michael Norkin of Harrison and Star. "It's facilitating one-to-one discussions at the booth."
The chance to don purple 3-D glasses and see some striking visuals may be what first grabs the audience's attention. But the sophisticated thrill-ride through the body and closeup of the drug's MOA is what keeps them watching. The DVD includes versions in English, German, Spanish, Italian, French, and Japanese, so professionals the world over can learn about anti-VEGF therapy while oohing and aahing at the visuals.
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.